This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2116133 (2021)
Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2116596 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Contrasting results with second-line CAR T cells in large B cell lymphoma. Nat Rev Clin Oncol 19, 71 (2022). https://doi.org/10.1038/s41571-021-00598-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00598-7